Aperio Group LLC lifted its position in Amgen, Inc. (NASDAQ:AMGN) by 2.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 481,640 shares of the medical research company’s stock after purchasing an additional 12,311 shares during the quarter. Aperio Group LLC owned about 0.07% of Amgen worth $99,839,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in AMGN. Beutel Goodman & Co Ltd. purchased a new position in Amgen during the second quarter valued at approximately $86,723,000. Mutual Advisors LLC raised its position in Amgen by 5.8% during the second quarter. Mutual Advisors LLC now owns 4,814 shares of the medical research company’s stock valued at $889,000 after acquiring an additional 265 shares in the last quarter. Argent Trust Co raised its position in Amgen by 31.8% during the second quarter. Argent Trust Co now owns 11,691 shares of the medical research company’s stock valued at $2,159,000 after acquiring an additional 2,818 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Amgen by 2.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 3,207,242 shares of the medical research company’s stock valued at $592,025,000 after acquiring an additional 72,205 shares in the last quarter. Finally, Perpetual Ltd raised its position in Amgen by 10.3% during the second quarter. Perpetual Ltd now owns 8,554 shares of the medical research company’s stock valued at $1,582,000 after acquiring an additional 800 shares in the last quarter. Hedge funds and other institutional investors own 82.38% of the company’s stock.
Shares of NASDAQ:AMGN opened at $201.80 on Friday. The company has a current ratio of 3.39, a quick ratio of 3.12 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $131.25 billion, a PE ratio of 16.04, a PEG ratio of 1.97 and a beta of 1.40. Amgen, Inc. has a 1 year low of $163.31 and a 1 year high of $210.19.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, July 26th. The medical research company reported $3.83 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.52 by $0.31. The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $5.73 billion. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The business’s revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.27 earnings per share. Research analysts anticipate that Amgen, Inc. will post 14.02 EPS for the current fiscal year.
AMGN has been the subject of several recent research reports. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $207.00 price target for the company in a research report on Tuesday, June 26th. Mizuho reissued a “buy” rating and issued a $200.00 price objective on shares of Amgen in a report on Friday, June 22nd. Jefferies Financial Group reissued a “buy” rating and issued a $200.00 price objective on shares of Amgen in a report on Monday, July 16th. Morgan Stanley raised their price objective on Amgen from $200.00 to $210.00 and gave the company a “buy” rating in a report on Friday, July 13th. Finally, Goldman Sachs Group reissued a “buy” rating and issued a $228.00 price objective on shares of Amgen in a report on Friday, July 27th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $204.90.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Further Reading: How to Invest in the Dividend Aristocrat Index
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.